Survey tests for all women will save on treatment costs

Women who carry a mutation in the geneBRCA Are at increased risk of developing both breast and ovarian cancer. The prevalence of the mutation in women of Ashkenazi descent in Israel reaches up to 2.5%. Diagnosis of carrying the mutation in the geneBRCA Is now done in a simple blood test and is extremely important, as knowledge about carrying allows us to offer effective preventative medicine, both by early diagnosis of breast cancer and by preventive surgeries for ovarian breast cancer.

In the first research paper published in the journal Cancer prevention research, We built a mathematical model with the help of which we examined the economic feasibility of testing a survey for the mutation carriers in the kindergartenBRCA For the entire population in Israel. The model we built is complex, and required the following into account of very many parameters and many costs required when treating women with cancer and carriers of the mutation. The results of the study showed that it would be profitable for the State of Israel to bear the costs of the survey for the entire female population in the country, thereby greatly saving on the costs of treating cancer that would be diagnosed early or avoided by risk-reducing surgeries.

Currently, all women of Ashkenazi descent in the State of Israel can undergo a screening test by being referred by the doctor treating the HMO. We hope that our work will facilitate the expansion of the canvas and allow the introduction of screening tests for the mutation in theBRCA Every woman in Israel, regardless of her background, will allow us to prevent many cases of cancer and help with early diagnosis in other cases.

50% of the offspring will also be carriers

In the second study published in the journal Reproductive Biology and Endocrinology, we examined the economic viability of performing in vitro fertilization (IVF) and pre-implantation diagnosis (PGD) diagnoses for couples in which one parent carried the mediation in the BRCA gene. Statistically about 50% of the offspring of carrier pairs, will also be carriers of the mutation in the BRCA gene. This treatment, which is currently not funded by the HMOs, will allow the selection of a fetus that is not a carrier of the mutation and will interrupt the chain of transmission of the defective gene to future generations.

The conclusions of the study showed that it would be worthwhile for the HMOs to finance the expensive treatment for pregnant couples, but at the same time save a lot on the treatment and follow-up of cancer that would be avoided by choosing an unborn fetus. The study is an important piece for couples in which one of the parents is a carrier of the mutation and who chooses to undergo the procedure in order to give birth to a newborn who is not pregnant and is currently forced to pay for the expensive treatments out of pocket.

The important studies were conducted, as always, in collaboration with Professor Moshe Leshano, a physician at Ichilov Hospital and a lecturer in the Faculty of Management at Tel Aviv University, the team of physicians from the Department of Gynecology and Oncology, Prof. Dan Grisero and Dr. Ido Laskov, and the team of physicians from the Ichilov Oncology Department. , Dr. Amir Sonnenblick and Dr. Shira Peleg-Hasson.

Dr. Nadav Mashen, Director of Laparoscopic Surgery at the Department of Gynecological Oncology, Ichilov

By Editor

Leave a Reply